



Reporting format update

Information for Doctors

Reporting format update for the Harmony® Prenatal Test

The recent introduction of the option for screening for the 22q11.2 deletion has prompted a review of the Harmony Prenatal Test report format. Some minor report changes have been made to improve the clarity of information provided to referring doctors, and to avoid potential confusion between the FORTE algorithm probability value (detailed below) and the post-test probability of a fetal chromosomal abnormality.

harmony®
PRENATAL TEST

Sonic Genetics
Quality is in our DNA

Kate Goodhealth
DOB: 14 Feb 1992 (26 yrs)
Lab ID: G2000007 NP19-00155
Phone: 24 Hurwath St
Address: BOWEN HILLS QLD 4006

Dr Test Doctor
H3501
FOSST/f--f--f--
Prenatal Department
24 Hurwath St
BOWEN HILLS QLD 4006

Your Ref
P Hickson H3501
Requested: 11 Mar 2018
Collection: 11 Mar 2018, 08:00 am
Received: 11 Mar 2018
Reported: 12 Apr 2018, 12:24 pm
Sample type: cDNA from plasma
Fetal Fraction: 5.2%
Gestation: 10 weeks 5 days (at collection)
IVF Status: Non-IVF Pregnancy
No. of fetuses: 1

HIGH RISK RESULT

Harmony® Prenatal Test Report

CHROMOSOME	RESULT	RECOMMENDATION
Trisomy 21 (T21)	Low Risk	Review results with patient
Trisomy 18 (T18)	Low Risk	Review results with patient
Trisomy 13 (T13)	Low Risk	Review results with patient
22q11.2 Microdeletion	High probability of a deletion	Genetic counselling and additional testing
Fetal Sex	No result possible	
Sex Chromosome Aneuploidy (SCA)	No result possible	

COMMENTS
The Harmony Prenatal Test is a screening test for the chromosomal abnormalities listed in the report above. This result should be considered in the context of all other clinical information regarding this pregnancy. Fetal chromosomal studies (eg, CVS or amniocentesis) are required to make a definitive diagnosis, following a high probability result. Fetal ultrasonography is recommended for patients with a high probability 22q11.2 deletion result. There are currently limited studies evaluating the positive predictive value (PPV) of a high risk result for 22q11.2 deletion. Results from sex analysis was not possible for this sample. Reliable sex chromosome analysis was not possible for this sample. This does not necessarily indicate an altered risk of sex chromosome aneuploidy. Fetal ultrasound could be considered. Repeat Harmony test is not generally recommended, please see www.sonicgenetics.com.au/htr for more information.
The negative predictive value (NPV) of each low risk result will vary with the patient's pre test probability. For example, with a pre test probability of 1/50, the theoretical NPV of a low risk result is >99.9% for each of the autosomal trisomies (13, 18, 21). With a pre test probability of 1/50, the theoretical NPV is >99.9% for each autosomal trisomy. Please see www.sonicgenetics.com.au/harmonyppv for more information.

Test Description
The Harmony Prenatal Test is a non-invasive prenatal screening (NIPS) test that screens for Down syndrome, Edwards syndrome, Patau syndrome, and sex chromosome aneuploidy (SCA) by analyzing cell-free fetal DNA (cffDNA) in the maternal blood. The test uses a targeted sequencing approach to identify copy number changes in the fetal genome. The test is performed on a maternal blood sample collected between 10 and 14 weeks of pregnancy. The test is performed on a maternal blood sample collected between 10 and 14 weeks of pregnancy. The test is performed on a maternal blood sample collected between 10 and 14 weeks of pregnancy. The test is performed on a maternal blood sample collected between 10 and 14 weeks of pregnancy.

Harmony Clinical Performance Data (Published Literature)

Abnormality	Detection Rate	False Positive Rate
T21	99.9%	< 0.1%
T18	99.9%	< 0.1%
T13	99.9%	< 0.1%
SCA	99.9%	< 0.1%
22q11.2	99.9%	< 0.1%

Issue 7, Mar 2018
Sonic Genetics Prenatal Test Report Number 1504

FORTE algorithm

FORTE (Fetal-Fraction Optimised Risk of Trisomy Evaluation) is the algorithm at the heart of the Harmony Prenatal Test.^{1,2} Targeted fragments are amplified from chromosomal regions of interest using DANSR (Digital Analysis of Selected Regions) assays.¹ The FORTE algorithm considers the relative intensity of DANSR assay signals, along with variance ('noise') in the data, and other measurements of data quality.

FORTE also incorporates maternal risk factors, the number of fetuses and, most importantly, the measured fetal fraction. In the new Harmony report, demographic information considered by the FORTE algorithm is grouped together in the top right-hand corner of the report. This is **coloured in blue rather than black**, to highlight that it is important to check the accuracy of this information (estimated gestation, IVF status and the number of fetuses).

FORTE algorithm probability value

FORTE produces a probability estimate for presence of each screened chromosomal aneuploidy, based on all of the factors outlined above.¹⁻⁴ The majority of low-risk FORTE scores are <0.01%, and the majority of high-risk scores are >99%. To ensure the highest test detection rate and lowest false-positive rate, a cut-off FORTE probability value of 1% is used to differentiate high-risk Harmony results from low-risk results.

This cut-off is applied to all Harmony tests. It was used in large clinical studies to determine the test performance characteristics — i.e. detection rate and false-positive rate. These test performance characteristics are provided in tabular form on each Harmony report, for each screened abnormality.

Probability of a chromosomal abnormality in the fetus versus FORTE probability value

The FORTE probability value reflects the odds that the tested cell-free DNA (cfDNA) sample is either trisomic or euploid. However, it does not directly provide the probability of whether the fetus is trisomic or not.

This is because cfDNA is derived from the placenta, and there are a number of biological factors which can cause discordance between the genetic status of cfDNA and the fetus. Examples include confined placental mosaicism, fetal mosaicism, maternal chromosome changes, and the presence of an unrecognised non-viable twin.

As with any screening test, the post-test probability that the fetus is affected when a non-invasive prenatal test returns a high-risk result will depend on two factors:

- 1) Test performance characteristics (detection rate/false-positive rate) – these are provided on each Harmony Prenatal Test report, *and*
- 2) The pre-test probability of the tested abnormality.

The higher the pre-test probability, the higher the likelihood is that a high-risk cfDNA result will reflect fetal genetic status. Conversely, in a patient with low pre-test probability, the likelihood that a high-risk cfDNA result reflects fetal genetic status is reduced.

Post-test probability for a high-risk result is sometimes known as the Positive Predictive Value (PPV) of the test — although PPV is a population-based statistic rather than an individualised post-test risk score.

In the same way, the likelihood that a fetus is unaffected when a non-invasive prenatal test returns a low-risk result will depend on both test performance characteristics, and on the pre-test probability of an abnormality. The risk of a false-negative result is low in all risk categories, but it is increased if there is a very high pre-test probability of a chromosomal abnormality — e.g. risk >1/10 on the combined first trimester screen, or presence of a major fetal structural abnormality on ultrasonography.

In addition, if clinical factors indicate a very high risk of a chromosomal abnormality, the possibility should be considered of an atypical abnormality, which is not screened for by Harmony but may be detected by invasive testing (chorionic villus sampling or amniocentesis).

New report format — Clear presentation of high- and low-risk results

The FORTE probability score was previously provided on Harmony reports as additional information. However, this could possibly be misinterpreted as test PPV for high-risk results, or test NPV for low-risk results.

For this reason, the new Harmony report does not provide the FORTE probability score, and instead states whether the result is high-risk (i.e. FORTE probability value >1%) or low-risk (FORTE probability value <1%) for each tested abnormality.

The post-test probability in the light of a high-risk (or low-risk) result will vary with the patient-specific pre-test probability, rather than the exact value of the FORTE probability score. If the FORTE probability value is still required for a particular patient, please contact the local Sonic Genetics laboratory.

In the new report format, an indicative PPV value from an Australian obstetric cohort tested by Harmony is provided for high-risk results⁵ (where data is available for that abnormality). For low-risk results, an example of estimated NPV, assuming a prior probability of 1/50 and 1/500, will be provided (NPV will be higher for patients at lower prior risk, and vice versa).

Further information on post-test probability is available on the Sonic Genetics website:
www.sonicgenetics.com.au/harmonyppv

References

1. Sparks et al. *Prenat Diagn.* 2012 Jan;32(1):3-9
2. Sparks et al. *Am J Obstet Gynecol.* 2012 Apr;206(4):319.e1-9
3. Juneau et al. *Fetal Diagn Ther.* 2014;36(4):282-6
4. Ashoor et al. *Am J Obstet Gynecol.* 2012 Apr;206(4):322.e1-5
5. McLennan et al. *ANZJOG.* 2016 Jan;56(1):22-28

For further information, including scientific and peer-reviewed publications, please refer to our website, www.sonicgenetics.com.au/nipt or call us on 1800 010 447

14 Giffnock Avenue, Macquarie Park, NSW 2113, Australia
T 1800 010 447 | E info@sonicgenetics.com.au
www.sonicgenetics.com.au

Non-invasive prenatal testing based on cell-free DNA analysis is not diagnostic: results should be confirmed by diagnostic testing. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. The Harmony Prenatal Test was developed by Ariosa Diagnostics. Sonic Genetics performs the Harmony Prenatal Test in Australia at our NATA-accredited Sullivan Nicolaides Pathology (SNP) laboratory. The Harmony Prenatal Test is included on the Australian Register of Therapeutic Goods.

© 2018 Roche Diagnostics.

HARMONY PRENATAL TEST and HARMONY are trademarks of Roche. All other trademarks are the property of their respective owners.

Printed April 2018